# Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

> **NCT02097225** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- BRAF V600E Mutation Present
- BRAF V600K Mutation Present
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Stage III Cutaneous Melanoma AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** Dabrafenib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Onalespib
- **OTHER:** Pharmacological Study
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02097225
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-29
- **Primary completion:** 2019-03-31
- **Final completion:** 2022-10-26
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Drug supply issues
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097225, "Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02097225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*